59440--3/1/2010--VECTOR_GROUP_LTD

related topics
{product, liability, claim}
{debt, indebtedness, cash}
{competitive, industry, competition}
{condition, economic, financial}
{control, financial, internal}
{personnel, key, retain}
{tax, income, asset}
{stock, price, operating}
{loan, real, estate}
{stock, price, share}
We are a holding company and depend on cash payments from our subsidiaries, which are subject to contractual and other restrictions, in order to service our debt and to pay dividends on our common stock. Our 11% senior secured notes contain restrictive covenants that limit our operating flexibility. Liggett faces intense competition in the domestic tobacco industry. Liggett s business is highly dependent on the discount cigarette segment. Liggett s market share is susceptible to decline. The domestic cigarette industry has experienced declining unit sales in recent periods. Liggett s cigarettes are subject to substantial and increasing regulation and taxation, which has a negative effect on revenue and profitability. The newly enacted Family Smoking Prevention and Tobacco Control Act may adversely affect our sales and operating profit. Litigation will continue to harm the tobacco industry. Individual tobacco-related cases have increased as a result of the Florida Supreme Court s ruling in Engle. Regulation and legislation may negatively impact sales of tobacco products and our financial condition. Liggett may be adversely affected by the 2004 legislation to eliminate the federal tobacco quota system. Excise tax increases adversely affect cigarette sales. Liggett may have additional payment obligations under the Master Settlement Agreement and its other settlement agreements with the states. Liggett may have additional payment obligations under its state settlements Vector Tobacco is subject to risks inherent in new product development initiatives. New Valley is subject to risks relating to the industries in which it operates. Potential new investments we may make are unidentified and may not succeed. We depend on our key personnel. We are exposed to risks from legislation requiring companies to evaluate their internal control over financial reporting. The price of our common stock may fluctuate significantly.

Full 10-K form ▸

related documents
59440--3/2/2009--VECTOR_GROUP_LTD
59440--2/29/2008--VECTOR_GROUP_LTD
864683--7/6/2007--CYBERONICS_INC
864683--1/5/2007--CYBERONICS_INC
784199--2/19/2009--CRYOLIFE_INC
754009--2/27/2007--SIERRA_HEALTH_SERVICES_INC
884909--3/12/2009--HOME_DIAGNOSTICS_INC
1050007--11/23/2010--NUTRACEUTICAL_INTERNATIONAL_CORP
885725--2/26/2010--BOSTON_SCIENTIFIC_CORP
918112--9/28/2010--NEUROBIOLOGICAL_TECHNOLOGIES_INC_/CA/
884629--2/25/2008--WATSON_PHARMACEUTICALS_INC
776008--3/16/2010--STAR_SCIENTIFIC_INC
784199--2/19/2010--CRYOLIFE_INC
884629--3/1/2007--WATSON_PHARMACEUTICALS_INC
884629--2/23/2009--WATSON_PHARMACEUTICALS_INC
1040666--3/16/2009--VNUS_MEDICAL_TECHNOLOGIES_INC
881464--2/27/2009--AMYLIN_PHARMACEUTICALS_INC
881464--2/26/2010--AMYLIN_PHARMACEUTICALS_INC
319240--3/16/2010--IRIS_INTERNATIONAL_INC
1104280--12/3/2010--SANGUI_BIOTECH_INTERNATIONAL_INC
811240--3/16/2009--BIOLASE_TECHNOLOGY_INC
350907--2/24/2010--THORATEC_CORP
811669--2/22/2008--UST_INC
797721--6/1/2010--VIASAT_INC
1040666--3/14/2008--VNUS_MEDICAL_TECHNOLOGIES_INC
1040666--3/30/2007--VNUS_MEDICAL_TECHNOLOGIES_INC
882873--9/17/2010--UROLOGIX_INC
863680--3/31/2009--CARDIOGENESIS_CORP_/CA
890846--5/28/2010--UROPLASTY_INC
884629--3/1/2010--WATSON_PHARMACEUTICALS_INC